Literature DB >> 3360524

Peripheral pulmonary vascular and airway abnormalities in adolescents with rheumatic mitral stenosis.

S G Haworth1, S M Hall, M Panja, M Patel.   

Abstract

Lung biopsy specimens were taken from 15 adolescents (aged 11-21 years), at the time a mitral valvotomy was performed. In addition to quantitative light microscopic studies three specimens were also examined by scanning and transmission electron microscopy. In all cases, the pulmonary vascular abnormalities were most marked in the capillary bed and in the vessels immediately proximal and distal to it. The capillaries showed a marked increase in basement membrane material at the blood/gas barrier, and were embedded in dense connective tissue within the alveolar walls. Intra-acinar and, to a lesser extent, pre- and post-acinar vessels showed an increase in muscularity, severe circumferential intimal fibrosis, and abnormally thick and dense adventitial connective tissue. The peripheral airways were encased in dense connective tissue, which appeared to compress them. Bronchial smooth muscle was increased. Six months after the mitral valvotomy was performed, the mean pulmonary arterial pressure had fallen from 42 mm Hg to 23 mm Hg. Despite this satisfactory haemodynamic result, the long-term effects of small airway compression on the growing lung indicate the need for early relief of mitral valve obstruction, possibly made easier by the new technique of balloon angioplasty.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3360524     DOI: 10.1016/0167-5273(88)90059-9

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  16 in total

Review 1.  Diffuse Alveolar Hemorrhage in Cardiac Diseases.

Authors:  Biplab K Saha; Woon H Chong
Journal:  Lung       Date:  2021-03-11       Impact factor: 2.584

2.  Changes in pulmonary circulation in severe bronchopulmonary dysplasia.

Authors:  A Bush; C M Busst; W B Knight; A A Hislop; S G Haworth; E A Shinebourne
Journal:  Arch Dis Child       Date:  1990-07       Impact factor: 3.791

3.  CHANGES IN PULMONARY VASCULATURE IN LUNG DISEASES WHICH LEAD TO PULMONARY HYPERTENSION.

Authors:  R B Batra; S K Basu
Journal:  Med J Armed Forces India       Date:  2017-06-26

Review 4.  Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment.

Authors:  Eva M Boorsma; Jozine M Ter Maaten; Kevin Damman; Wilfried Dinh; Finn Gustafsson; Steven Goldsmith; Daniel Burkhoff; Faiez Zannad; James E Udelson; Adriaan A Voors
Journal:  Nat Rev Cardiol       Date:  2020-05-15       Impact factor: 32.419

5.  Left ventricular failure produces profound lung remodeling and pulmonary hypertension in mice: heart failure causes severe lung disease.

Authors:  Yingjie Chen; Haipeng Guo; Dachun Xu; Xin Xu; Huan Wang; Xinli Hu; Zhongbing Lu; Dongmin Kwak; Yawei Xu; Roland Gunther; Yuqing Huo; E Kenneth Weir
Journal:  Hypertension       Date:  2012-04-16       Impact factor: 10.190

Review 6.  Pulmonary Limitations in Heart Failure.

Authors:  Ivan Cundrle; Lyle J Olson; Bruce D Johnson
Journal:  Clin Chest Med       Date:  2019-06       Impact factor: 2.878

7.  Mediastinal lymphadenopathy in patients undergoing cardiac transplant evaluation.

Authors:  Nicholas J Pastis; Adrian B Van Bakel; Timothy M Brand; James G Ravenel; Gregory E Gilbert; Gerard A Silvestri; Marc A Judson
Journal:  Chest       Date:  2010-10-21       Impact factor: 9.410

Review 8.  Pulmonary hypertension caused by pulmonary venous hypertension.

Authors:  Thomas J Kulik
Journal:  Pulm Circ       Date:  2014-12       Impact factor: 3.017

9.  Does the bronchial circulation contribute to congestion in heart failure?

Authors:  Maile Ceridon; Adam Wanner; Bruce D Johnson
Journal:  Med Hypotheses       Date:  2009-05-22       Impact factor: 1.538

Review 10.  Lung morphology and surfactant function in cardiogenic pulmonary edema: a narrative review.

Authors:  Kenneth Nugent; Logan Dobbe; Rubayat Rahman; Mohamed Elmassry; Pablo Paz
Journal:  J Thorac Dis       Date:  2019-09       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.